MediWound (NASDAQ:MDWD) Stock Crosses Below Two Hundred Day Moving Average - Here's Why

Key Points

• MediWound shares fell below their 200-day moving average, trading as low as $12.85 versus the $15.72 average, and last changing hands near $12.97.
• Analyst sentiment is mixed: MediWound has an overall “Hold” rating and a $33 consensus price target, with ratings ranging from “Strong Sell” to “Buy.”
• The company reported a quarterly loss of $0.77 per share, narrowly missing estimates, although revenue of $3.09 million exceeded expectations; analysts forecast a full-year loss of $2.31 per share.

MediWound Ltd. (NASDAQ:MDWD - Get Free Report)'s share price passed below its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $15.72 and traded as low as $12.85. MediWound shares last traded at $12.97, with a volume of 80,358 shares traded.

Wall Street Analysts Forecast Growth

MDWD has been the subject of several research analyst reports. Wall Street Zen lowered shares of MediWound from a "sell" rating to a "strong sell" rating in a research note on Saturday, August 15th. Weiss Ratings reissued a "sell (d-)" rating on shares of MediWound in a research note on Friday, July 17th. HC Wainwright reiterated a "buy" rating and set a $36.00 price objective on shares of MediWound in a report on Thursday, May 28th. Finally, Oppenheimer reissued an "outperform" rating and set a $30.00 price objective (down from $32.00) on shares of MediWound in a report on Friday, August 14th. Two analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, MediWound presently has an average rating of "Hold" and a consensus target price of $33.00.

MediWound Stock Down 0.2%

The company has a market capitalization of $166.66 million, a P/E ratio of -7.21 and a beta of 0.15. The business's 50-day moving average is $14.24 and its two-hundred day moving average is $15.72.

MediWound (NASDAQ:MDWD - Get Free Report) last issued its quarterly earnings data on Thursday, August 13th. The biopharmaceutical company reported ($0.77) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.76) by ($0.01). The firm had revenue of $3.09 million during the quarter, compared to the consensus estimate of $2.59 million. MediWound had a negative return on equity of 47.24% and a negative net margin of 170.10%. Analysts predict that MediWound Ltd. will post -2.31 EPS for the current year.

Insider Buying and Selling at MediWound

In other MediWound news, Director David Morton Fox bought 3,537 shares of MediWound stock in a transaction dated Monday, June 1st. The stock was bought at an average cost of $14.11 per share, with a total value of $49,907.07. Following the completion of the acquisition, the director directly owned 22,283 shares in the company, valued at approximately $314,413.13. The trade was a 18.87% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. 9.20% of the stock is owned by insiders.

Institutional Trading of MediWound

A number of hedge funds have recently bought and sold shares of MDWD. Quarry LP bought a new position in MediWound in the 4th quarter valued at $26,000. BNP Paribas Financial Markets raised its stake in shares of MediWound by 90.4% during the 3rd quarter. BNP Paribas Financial Markets now owns 1,523 shares of the biopharmaceutical company's stock worth $27,000 after purchasing an additional 723 shares during the period. California State Teachers Retirement System raised its stake in shares of MediWound by 281.4% during the 2nd quarter. California State Teachers Retirement System now owns 2,014 shares of the biopharmaceutical company's stock worth $30,000 after purchasing an additional 1,486 shares during the period. Russell Investments Group Ltd. boosted its holdings in shares of MediWound by 69.1% in the 2nd quarter. Russell Investments Group Ltd. now owns 1,588 shares of the biopharmaceutical company's stock worth $31,000 after buying an additional 649 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of MediWound by 22.4% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 5,452 shares of the biopharmaceutical company's stock worth $85,000 after buying an additional 999 shares during the last quarter. 46.83% of the stock is currently owned by institutional investors.

MediWound Company Profile

MediWound Ltd. NASDAQ: MDWD is a biopharmaceutical company headquartered in Yavne, Israel, specializing in the development and commercialization of innovative enzymatic therapies for burn and wound management. Since its establishment, the company has focused on advancing proteolytic enzyme technology to address critical needs in debridement and tissue repair. MediWound operates research and development facilities in Israel and maintains commercial offices in the United States to support its global market presence.

The company's lead product, NexoBrid®, is an enzyme-based debriding agent designed to selectively remove burn eschar without harming viable tissue.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source